Compound ID | 961
Class: Beta-lactamase inhibitor (penem)
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Triazolyl methylene penem that is a potent inhibitor of TEM and SHV type plasmid β-lactamases and also chromosomal Cephalosporinases of Enterobacter and Citrobacter. In combination with amoxycillin alowed activity against resistant (β-lactamase producing) bacteria such as Xanthamonas maltophilia, B. fragilis and more |
| Combined with other compounds: | No antimicrobial activity (2) so would need to have been paired with a β-lactam |
| Institute where first reported: | Beecham Pharmaceuticals (GSK, US) |
| Year first mentioned: | 1987 |
| Highest development stage: | Phase 1 |
| Development status: | Inactive |
| Reason dropped: | No antimicrobial activity (2)-by 2004 it was no longer in clinical development but may well have been discontinued earlier. Whilst it is a very potent inhibitor, it is quickly eliminated with an extrapolated terminal t½ of 31mins (1). BRL 42715, its development has been discontinued as a result of its low serum half-life (2) |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/23705463 |
| Guide to Pharmacology: | BRL-42715 |
| Citations: |
|